Our centers of expertise span therapeutic areas, markets and geographies, and are underpinned by these four core research principles:
Members of Research Partnership’s Oncology Centre of Excellence attended ESMO Congress 2024 in September, along with other representatives from ...
This Acute Myeloid Leukemia infographic offers an introduction to the real-world patient data collected by our Therapy Watch study.
Findings from a study conducted by Dr. Chris Gaj, Vice President at Research Partnership, has been published in Clinical Genitourinary Cancer.
Tania Rodrigues investigates the market access and commercialization potential for manufacturers of CAR-T therapies.
Renal Cell Carcinoma Key data readouts/events March 2023: Phase III CONTACT-03 study evaluating CABOMETYX (cabozantinib) plus TECENTRIQ
Research Partnership and Bristol Myers Squibb were pronounced the winners in the “Healthcare Research” category at the 2022 MRS awards.
The report is an excerpt of our ethnographic research of oncology patients in the UK with head and neck and gastric cancer.
How we helped our client to develop a trackable index for patients newly diagnosed with multiple myeloma to track/measure the patient experience.
Chimeric antigen receptor (CAR)-T continues to take center stage as a paradigm shift in the treatment of cancer.
Our client was developing a CAR-T therapy in MM across multiple lines of therapy.
Immuno-oncology is the new frontier in cancer treatment. This infographic is a snapshot of the PD-1/PD-L1 market.
Our client wanted to capture patient narratives; individual and shared experiences of living with head and neck cancer.
Rapport is our monthly newsletter where we share our latest expertise and experience.
